59 results on '"Althouse, Sandra"'
Search Results
2. Genomic alterations and clinical outcomes in patients with non-clear cell RCC: Indiana University experience.
3. Management of progressive brain metastases in patients (pts) with relapsed germ-cell tumor (GCT) treated with salvage high-dose chemotherapy (HDCT).
4. Clinical features, genomic alterations, and survival outcomes for variant histology urothelial carcinoma.
5. The impact of smoking status on genomic profile in patients with renal cell carcinoma.
6. Disparities in breast cancer prevention initiatives at a comprehensive cancer center: Who are we serving?
7. Updated safety and efficacy analysis comparing elderly vs nonelderly patients treated with consolidation nivolumab or nivolumab plus ipilimumab after chemoradiation for unresectable stage III NSCLC from the BTCRC LUN 16-081 clinical trial.
8. Management of Residual Nonretroperitoneal Disease in Postchemotherapy Nonseminomatous Germ-Cell Tumors
9. Impact of body mass index (BMI) on clinical and toxicity outcomes in patients with relapsed metastatic germ-cell tumor (GCT) undergoing high-dose chemotherapy (HDCT) with peripheral blood stem cell transplant (PBSCT).
10. Safety of pegfilgrastim in patients with metastatic germ-cell tumor receiving combination chemotherapy containing bleomycin.
11. Predictors of PSA response to Lu177-PSMA-617 in metastatic castration-resistant prostate cancer.
12. Genomic alterations in metastatic renal cell carcinoma (mRCC): Impact on survival and clinical outcomes.
13. Primary mediastinal seminoma: Treatment and survival outcomes.
14. Salvage high-dose chemotherapy (HDCT) for relapsed primary mediastinal nonseminomatous germ-cell tumors (PMNSGCT).
15. Adverse health outcomes (AHO) in testis cancer survivors (TCS) following high-dose chemotherapy (HDCT) and autologous stem cell transplant.
16. Consolidation nivolumab plus ipilimumab or nivolumab alone following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: BTCRC LUN 16-081.
17. Management of residual nonretroperitoneal disease in nonseminomatous germ-cell tumors (NSGCT).
18. Phase II trial of atezolizumab (A) + carboplatin (C) + pemetrexed (P) + bevacizumab (B) in pts with stage IV non-squamous non-small cell lung cancer (NSq-NSCLC): Big Ten Cancer Research Consortium Study LUN 17-139.
19. A phase II trial of chemotherapy plus pembrolizumab in patients with advanced NSCLC previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.
20. Surveillance after complete response in patients with metastatic non-seminomatous germ-cell tumor (NSGCT).
21. Late relapse of germ cell tumors: Detection and treatment outcomes.
22. Prediction model for brain metastasis (BM) in patients with metastatic germ-cell tumors (mGCT) accounting for size of pulmonary metastases.
23. Maintenance oral etoposide (VP-16) after high-dose chemotherapy (HDCT) for patients with relapsed metastatic germ-cell tumors (mGCT).
24. Standard-dose salvage chemotherapy in patients with refractory metastatic germ-cell tumors (mGCT) progressing after high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplant (PBSCT).
25. The association between STK11/LKB1 and/or KEAP1 mutations and response to PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer (NSCLC).
26. Inhibiting fatty acid synthase in operable triple negative breast cancer.
27. Immunomodulation by HDAC inhibition: Results from a phase I study with entinostat in combination with atezolizumab and bevacizumab in metastatic renal cell carcinoma patients.
28. Model to predict brain metastasis (BM) in patients with metastatic germ-cell tumors (mGCT).
29. The association between immune-related adverse events and efficacy outcomes with consolidation pembrolizumab after chemoradiation in patients with stage III NSCLC: an analysis from HCRN LUN 14-179.
30. High-dose chemotherapy (HDCT) and peripheral-blood stem cell transplant (PBSCT) in patients age 40 or older with relapsed metastatic germ-cell tumors (mGCT).
31. Prognostic significance of rate of tumor marker (TM) decline during high-dose chemotherapy (HDCT) for relapsed germ cell tumors (rGCT).
32. iMETX (Individualized Metabolic RX): An environmental intervention to increase energy expenditure in breast cancer survivors.
33. Prognostic value of serum tumor marker (STM) rate of decline during high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplant (PBSCT) for relapsed germ-cell tumors (rGCT).
34. Survival and toxicity outcomes in patients age 40 or older with relapsed metastatic germ cell tumors (mGCT) treated with high-dose chemotherapy (HDCT) and autologous peripheral-blood stem cell transplant (PBSCT).
35. PET/CT assessment of tumor perfusion (TP) in metastatic renal cell cancer (RCC) patients (pts) on sunitinib (S) using 62Cu-ETS.
36. Adverse health outcomes (AHO) after modern cisplatin-based chemotherapy (CHEM) compared to surgery-only: A study of 503 testicular cancer survivors (TCS).
37. Long-term survival comparison of stereotactic radiotherapy versus surgery for elderly patients with clinical stage T1-T2 non-small cell lung cancer.
38. Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179.
39. A phase II study of BKM120 (buparlisib) in relapsed or refractory thymomas.
40. Phase II trial of pembrolizumab in patients (pts) with incurable platinum refractory germ cell tumors (GCT).
41. High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience
42. Risk stratification of clinical stage I (CSI) non-seminomatous germ cell testicular tumors (NSGCT): A retrospective analysis of experience at Indiana University (IU).
43. High-dose chemotherapy (HDCT) and autologous peripheral-blood stem cell transplant (PBSCT) for relapsed metastatic germ-cell tumors (mGCT): The Indiana University (IU) experience.
44. Survival outcomes of patients with metastatic germ cell tumor (mGCT) treated from 1998 to 2012: The Indiana University (IU) experience.
45. Real-world data for predictors of PSA response to Lu177-PSMA-617 in metastatic castration resistant prostate cancer.
46. Bone metastasis in patients with germ-cell tumors: Analysis of survival outcomes and prognostic factors.
47. Clinical outcomes in patients with post-chemotherapy residual non-retroperitoneal (RP) disease in non-seminomatous germ-cell tumors (NSGCT).
48. Association of immune-related adverse events and efficacy outcomes in phase II trial of consolidation nivolumab plus ipilimumab or nivolumab alone after chemoradiation in patients with unresectable stage III non–small-cell lung cancer (NSCLC).
49. Three-dimensional lymph node volume and craniocaudal lymph node length as an independent risk factor for recurrence or presence of micrometastatis in clinical stage I non-seminomatous germ cell tumors: A retrospective study.
50. A retrospective analysis of patients with metastatic germ cell tumor (GCT) treated at Indiana University (IU) from 2000 to 2012.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.